lavoltidine
Small moleculeexperimental
Lavoltidine (INN, USAN, BAN; previously known as loxtidine; development code AH-23,844) is a highly potent and selective H2 receptor antagonist which was under development by Glaxo Wellcome (now GlaxoSmithKline) as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents. — Wikipedia
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2006 (NCT00405119)
Timeline
Indications
Studied for
Mechanism of action
- Histamine H2 receptorINHIBITOR
HRH2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1nc(CO)nc1NCCCOc1cccc(CN2CCCCC2)c1- Mol. weight
- 359.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLavoltidine ↗
- ChEMBLCHEMBL2110857 ↗
Also known as
- lavoltidine
- lavoltidine
- lavoltidine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00551473 | Phase 1 | May 1, 2007 | GlaxoSmithKline |
| NCT00405119 | Phase 2 | May 1, 2006 | GlaxoSmithKline |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 2 | 2 | 2 | 2006 |
1 organizations
Page 1 / 1